Insulet Expects Q3 Revenue Growth Of 18%-21%; Raising Its FY23 Expected Revenue Growth Of 22%-25% (Previously 18%-22%)
Portfolio Pulse from Happy Mohamed
Insulet Corporation has raised its revenue growth expectations for FY23 to 22%-25%, up from the previous 18%-22%. The company also expects Q3 revenue growth of 18%-21%. The growth is expected to be driven by its Omnipod product line, with U.S. Omnipod expected to grow 33%-36% and International Omnipod 7%-10%. However, the Drug Delivery product line is expected to decline by 50%-45%. The company reaffirms its gross margin of 65%-66% and expects an operating margin in the high-single digits for FY23.
August 08, 2023 | 8:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Insulet's raised revenue growth expectations for FY23 and Q3, driven by its Omnipod product line, could positively impact its stock. However, the expected decline in the Drug Delivery product line could offset some of this positive impact.
The raised revenue growth expectations indicate strong performance, particularly from the Omnipod product line, which could boost investor confidence and drive the stock price up. However, the expected decline in the Drug Delivery product line could be a concern for investors and may offset some of the positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100